Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2011. The report details a specific share repurchase transaction executed on November 9, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback activity:
- Shares Purchased: 850,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,394 pence per share; lowest price paid was 1,367 pence per share.
- Treasury Holdings (Settled): 515,727,927 shares (9.25% of total issued share capital).
- Treasury Holdings (Including Unsettled): 518,377,927 shares (10.25% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,056,862,125 shares.
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 850,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 9.25% of issued capital and 10.25% of total voting rights when including unsettled transactions. The filing does not provide comparative data against prior periods for these specific metrics.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (515,727,927 settled) against the company's latest capital structure reports.
- Confirm the calculation of total voting rights (5,056,862,125 shares in issue) for compliance with disclosure thresholds.
- Review the authority granted at the May 5, 2011 Annual General Meeting to ensure the repurchase was within the approved limits.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or interim reports for revenue and profit metrics.